Request Demo
Last update 02 Aug 2025
Darbepoetin alfa biosimilar(Biocad Medical, Inc.)
Last update 02 Aug 2025
Overview
Basic Info
Drug Type Biosimilar, Colony-stimulating factors |
Synonyms Darbepoetin alfa biosimilar, BCD 066, BCD-066 |
Target |
Action agonists |
Mechanism EPO receptor agonists(Erythropoietin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 54492
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Darbepoetin alfa biosimilar(Biocad Medical, Inc.)NCT03693950
A Double-blind, Randomized, Controlled Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Multiple Intravenous Injections of BCD-066 and Aranesp® in Healthy Volunteers
NCT02506868
Multicenter Double-blind Randomized Parallel Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp (Amgen Europe B.V., Netherlands) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
100 Clinical Results associated with Darbepoetin alfa biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Translational Medicine associated with Darbepoetin alfa biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Patents (Medical) associated with Darbepoetin alfa biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Deals associated with Darbepoetin alfa biosimilar(Biocad Medical, Inc.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anemia | Phase 3 | Russia | 08 Aug 2015 | |
| Kidney Failure, Chronic | Phase 3 | Russia | 08 Aug 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 57 | (BCD-066 1 µg/kg) | iwbxoavzwa(vrdmzgsdpt) = gswoqfwrvi rkxvlgguvn (pslkajmvnt, glindrprzt - pzrvfssojx) View more | - | 01 Jul 2019 | |
(Aranesp 1 µg/kg) | iwbxoavzwa(vrdmzgsdpt) = ymuvacleei rkxvlgguvn (pslkajmvnt, owrwifdexx - gbaruacvzp) View more | ||||||
Phase 3 | 196 | (BCD-066) | qncermquyc(unwrrdywtc) = huoniqxfco jjtyadwkye (xruwscegmd, 10.941) View more | - | 30 May 2019 | ||
(Aranesp) | qncermquyc(unwrrdywtc) = dijjpsorqn jjtyadwkye (xruwscegmd, 8.987) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free